Loading company
Just reported
From Lifecore Biomedical's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$25.3M
-19% y/y
-26% q/q
Guided
—
No guide given
Actual
-$1.08
Guided
—
No guide given
Actual
-$894K
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Lifecore Biomedical is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.5BA
NBIXNeurocrine Biosciences, Inc.$17.6BA+
ELANElanco Animal Health Incorporated$13.2BA
KNSAKiniksa Pharmaceuticals International, plc$8.1BA+
LQDALiquidia Corporation$5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now ABuilt from Lifecore Biomedical, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Grade F
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 38 quarters of Lifecore Biomedical, Inc.’s grade history. The other 36 go back to January 2017.
